食品药品监管总局提醒关注苯溴马隆的肝损害风险

2015-01-27 佚名 CFDA

苯溴马隆临床上主要用于原发性和继发性高尿酸血症、各种原因引起的痛风以及痛风性关节炎非急性发作期的治疗,目前主要在德国和日本、新加坡等一些亚洲国家使用。国家药品不良反应监测数据库分析显示,苯溴马隆的严重不良反应中肝损害问题比较突出。根据国内药品不良反应监测及国外监管措施情况,食品药品监管总局组织开展了苯溴马隆的风险效益评估,认为苯溴马隆在我国治疗痛风或高尿酸血症的获益仍大于风险。 国家食品药品监督

苯溴马隆临床上主要用于原发性和继发性高尿酸血症、各种原因引起的痛风以及痛风性关节炎非急性发作期的治疗,目前主要在德国和日本、新加坡等一些亚洲国家使用。国家药品不良反应监测数据库分析显示,苯溴马隆的严重不良反应中肝损害问题比较突出。根据国内药品不良反应监测及国外监管措施情况,食品药品监管总局组织开展了苯溴马隆的风险效益评估,认为苯溴马隆在我国治疗痛风或高尿酸血症的获益仍大于风险。

国家食品药品监督管理总局建议如下:

1、医护人员在使用苯溴马隆时,应从低剂量开始;治疗期间定期进行肝功能检查;避免同其他具有肝毒性的药物合用,减少严重不良反应的发生。

2、患者用药期间,应注意肝损害的症状和体征,如出现食欲不振、恶心、呕吐、全身倦怠感、腹痛、腹泻、发热、尿浓染、眼球结膜黄染等,应及时就诊,必要时检查肝功能并进行相应治疗。

3、药品生产企业加强药品不良反应监测和临床安全用药的宣传,确保产品的安全性信息及时传达给患者和医生。

小贴士:

一、苯溴马隆是什么药品,主要用于治疗什么疾病?

苯溴马隆是苯骈呋喃衍生物,它是通过抑制近端肾小管对尿酸的重吸收,以利于尿酸排泄,从而降低血中尿酸浓度的。临床上主要用于原发性和继发性高尿酸血症、各种原因引起的痛风以及痛风性关节炎非急性发作期。

二、苯溴马隆有哪些不良反应?

苯溴马隆的不良反应主要有:腹泻、胃部不适、恶心等消化系统症状;风团、斑疹、潮红、瘙痒等皮肤过敏症;肝功能异常及谷草转氨酶、谷丙转氨酶及碱性磷酸酶升高。

三、使用苯溴马隆时有哪些禁忌?

使用苯溴马隆的禁忌有:中度至重度肝功能损害者(肾小球滤过滤低于20ml/min)以及患有肾结石的患者,孕妇或有妊娠可能的妇女以及哺乳期妇女。

四、使用苯溴马隆有哪些注意事项?

1.出现持续性腹泻应停药。
2.不能在痛风急性发作期服用,因为开始治疗阶段,随着组织中尿酸溶出,有可能加重病症。
3.为了避免治疗初期痛风急性发作,建议在给药初期合用秋水仙碱或抗炎药。
4.治疗期间需大量饮水以增加尿量(治疗初期饮水量不得少于1.5-2升),以免在排泄的尿中由于尿酸过多导致尿酸结晶。定期测量尿液的酸碱度,为促进尿液碱化,可酌情给予碳酸氢钠或枸橼酸合剂,并注意酸碱平衡,病人尿液PH应调节在6.2~6.8之间。
5.在开始治疗时有大量尿酸随尿排出,因此在此时的用药剂量要小(起始剂量)。
6.长期用药时,应定期检查肝功能。
7.应避免与其他肝损害药物同时使用。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1635738, encodeId=6c531635e38a8, content=<a href='/topic/show?id=b7128123013' target=_blank style='color:#2F92EE;'>#肝损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81230, encryptionId=b7128123013, topicName=肝损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a32e22523419, createdName=ms9476844295372110, createdTime=Tue Sep 29 05:17:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032408, encodeId=6b1a2032408db, content=<a href='/topic/show?id=279210098931' target=_blank style='color:#2F92EE;'>#食品药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100989, encryptionId=279210098931, topicName=食品药品监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Mar 15 03:17:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672219, encodeId=c0b316e221934, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Fri Sep 11 18:17:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295126, encodeId=444c1295126d5, content=<a href='/topic/show?id=f1a68e07003' target=_blank style='color:#2F92EE;'>#苯溴马隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87070, encryptionId=f1a68e07003, topicName=苯溴马隆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Jan 29 05:17:00 CST 2015, time=2015-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371432, encodeId=c43c13e143232, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 29 05:17:00 CST 2015, time=2015-01-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1635738, encodeId=6c531635e38a8, content=<a href='/topic/show?id=b7128123013' target=_blank style='color:#2F92EE;'>#肝损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81230, encryptionId=b7128123013, topicName=肝损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a32e22523419, createdName=ms9476844295372110, createdTime=Tue Sep 29 05:17:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032408, encodeId=6b1a2032408db, content=<a href='/topic/show?id=279210098931' target=_blank style='color:#2F92EE;'>#食品药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100989, encryptionId=279210098931, topicName=食品药品监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Mar 15 03:17:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672219, encodeId=c0b316e221934, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Fri Sep 11 18:17:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295126, encodeId=444c1295126d5, content=<a href='/topic/show?id=f1a68e07003' target=_blank style='color:#2F92EE;'>#苯溴马隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87070, encryptionId=f1a68e07003, topicName=苯溴马隆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Jan 29 05:17:00 CST 2015, time=2015-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371432, encodeId=c43c13e143232, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 29 05:17:00 CST 2015, time=2015-01-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1635738, encodeId=6c531635e38a8, content=<a href='/topic/show?id=b7128123013' target=_blank style='color:#2F92EE;'>#肝损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81230, encryptionId=b7128123013, topicName=肝损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a32e22523419, createdName=ms9476844295372110, createdTime=Tue Sep 29 05:17:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032408, encodeId=6b1a2032408db, content=<a href='/topic/show?id=279210098931' target=_blank style='color:#2F92EE;'>#食品药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100989, encryptionId=279210098931, topicName=食品药品监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Mar 15 03:17:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672219, encodeId=c0b316e221934, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Fri Sep 11 18:17:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295126, encodeId=444c1295126d5, content=<a href='/topic/show?id=f1a68e07003' target=_blank style='color:#2F92EE;'>#苯溴马隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87070, encryptionId=f1a68e07003, topicName=苯溴马隆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Jan 29 05:17:00 CST 2015, time=2015-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371432, encodeId=c43c13e143232, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 29 05:17:00 CST 2015, time=2015-01-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1635738, encodeId=6c531635e38a8, content=<a href='/topic/show?id=b7128123013' target=_blank style='color:#2F92EE;'>#肝损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81230, encryptionId=b7128123013, topicName=肝损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a32e22523419, createdName=ms9476844295372110, createdTime=Tue Sep 29 05:17:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032408, encodeId=6b1a2032408db, content=<a href='/topic/show?id=279210098931' target=_blank style='color:#2F92EE;'>#食品药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100989, encryptionId=279210098931, topicName=食品药品监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Mar 15 03:17:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672219, encodeId=c0b316e221934, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Fri Sep 11 18:17:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295126, encodeId=444c1295126d5, content=<a href='/topic/show?id=f1a68e07003' target=_blank style='color:#2F92EE;'>#苯溴马隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87070, encryptionId=f1a68e07003, topicName=苯溴马隆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Jan 29 05:17:00 CST 2015, time=2015-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371432, encodeId=c43c13e143232, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 29 05:17:00 CST 2015, time=2015-01-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1635738, encodeId=6c531635e38a8, content=<a href='/topic/show?id=b7128123013' target=_blank style='color:#2F92EE;'>#肝损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81230, encryptionId=b7128123013, topicName=肝损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a32e22523419, createdName=ms9476844295372110, createdTime=Tue Sep 29 05:17:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032408, encodeId=6b1a2032408db, content=<a href='/topic/show?id=279210098931' target=_blank style='color:#2F92EE;'>#食品药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100989, encryptionId=279210098931, topicName=食品药品监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Mar 15 03:17:00 CST 2015, time=2015-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672219, encodeId=c0b316e221934, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Fri Sep 11 18:17:00 CST 2015, time=2015-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295126, encodeId=444c1295126d5, content=<a href='/topic/show?id=f1a68e07003' target=_blank style='color:#2F92EE;'>#苯溴马隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87070, encryptionId=f1a68e07003, topicName=苯溴马隆)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Jan 29 05:17:00 CST 2015, time=2015-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371432, encodeId=c43c13e143232, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jan 29 05:17:00 CST 2015, time=2015-01-29, status=1, ipAttribution=)]
    2015-01-29 zhouqu_8

相关资讯

保健品致药物性肝损害1例报道

  病史摘要   患者为女性,46岁。因“反复肝功能异常1年”入院。   患者1年前体检发现肝功异常,γ-谷氨酰转移酶(γ-GT)为90 U/L, 丙氨酸氨基转移酶(ALT )为37 U/L,天冬氨酸氨基转移酶(AST)为35 U/L,碱性磷酸酶(ALP)为98 U/L ,总蛋白 

CFDA全新药物警戒:替莫唑胺的肝损害风险

2014年5月7日,加拿大卫生部(Health Canada)向医疗保健专业人员发布信息,警示替莫唑胺的肝损害风险。替莫唑胺是一种抗肿瘤药物,用于联合放射治疗新诊断的成人多形性成胶质细胞瘤,并可维持用药;也可用于治疗有证据证明经标准治疗后复发或出现疾病进展的多形性成胶质细胞瘤或间变型星形细胞瘤的成年患者。从1994年1月19日替莫唑胺上市到2013年3月15日,共收到44例接受替莫唑胺治疗后确认为

药监局:关注苯溴马隆的肝损害风险

苯溴马隆临床上主要用于原发性和继发性高尿酸血症、各种原因引起的痛风以及痛风性关节炎非急性发作期的治疗,目前主要在德国和日本、新加坡等一些亚洲国家使用。国家药品不良反应监测数据库分析显示,苯溴马隆的严重不良反应中肝损害问题比较突出。根据国内药品不良反应监测及国外监管措施情况,食品药品监管总局组织开展了苯溴马隆的风险效益评估,认为苯溴马隆在我国治疗痛风或高尿酸血症的获益仍大于风险。 国家食品药

肝损害及乙型肝炎再活动1例

  病历摘要   现病史 患者女性,57岁,因胃脘不适3个月、乏力1个月于2011年8月11日就诊。患者20余年前感染乙型肝炎病毒(HBV),定期到我院随访。近10年来多次随访,肝功能均正常,HBV DNA< 500拷贝/毫升,HBsAg(+),HBeAg(-),HBeAb(+)。诊断为非活动性HBsAg携带者。   2011年3月患者在家不慎滑倒致